Imagine how many lives you save: Angiotensin-converting enzyme inhibition for atherosclerotic vascular disease in the present era of risk reduction

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 6, 2011, Pages 883-897

  Ennezat, Pierre Vladimir ^a   Vannesson, Claire ^a   Bouabdallaoui, Nadia ^a   Maréchaux, Sylvestre ^a,c   Asseman, Philippe ^a   Lejemtel, Thierry H ^b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITÉ CATHOLIQUE DE LILLE   (France)

Author keywords

angiotensin converting enzyme inhibitors; heart failure; hypertension; left ventricular dysfunction; myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; INDAPAMIDE; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; SIMVASTATIN; TRANDOLAPRIL;

ACUTE HEART FAILURE; ACUTE HEART INFARCTION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; STROKE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 79952773487     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.543675     Document Type: Review

References (61)

1. Pfeffer MA, Braunwald E, Moye LA, et al. The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992;327(10):669-77
2. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;12(5):293-302
3. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327(10):685-91
4. Dzau VJ. Pathobiology of atherosclerosis and plaque complications. Am Heart J 1994;128(6 Pt 2):1300-4
5. Diet F, Pratt RE, Berry GJ, et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996;94(11):2756-67 (Pubitemid 26411739)
6. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol 1990;15(Suppl 5):S65-72 (Pubitemid 20159139)
7. Chobanian AV, Haudenschild CC, Nickerson C, Drago R Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990;15(3):327-31 (Pubitemid 20097461)
8. Feener EP, Northrup JM, Aiello LP, King GL. Angiotensin II induces plasminogen activator inhibitor-1 and-2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 1995;95(3):1353-62
9. Wall TM, Sheehy R, Hartman JC Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther 1994;270(2):681-9 (Pubitemid 24271382)
10. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996;94(3):258-65 (Pubitemid 26266107)
11. Lonn E. Modifying the natural history of atherosclerosis: the SECURE trial. Int J Clin Pract Suppl 2001;(117):13-18
12. Rouleau JL, Warnica WJ, Baillot R, et al. Effects of angiotensin- converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery. Circulation 2008;117(1):24-31 (Pubitemid 350291178)
13. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004;292(18):2217-25
14. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351(20):2058-68
15. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342(8875):821-8
16. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333(25):1670-6 (Pubitemid 26001955)
17. MacMahon S, Sharpe N, Gamble G, et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J Am Coll Cardiol 2000;36(2):438-43 (Pubitemid 30624005)
18. Kjoller-Hansen L, Steffensen R, Grande P. The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES). J Am Coll Cardiol 2000;35(4):881-8 (Pubitemid 30189917)
19. Teo KK, Burton JR, Buller CE, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000;102(15):1748-54
20. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342(3):145-53
21. PROGRESS Collaborative group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358(9287):1033-41
22. Oosterga M, Voors AA, Pinto YM, et al. Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). QUinapril on Vascular Ace and Determinants of Ischemia. Am J Cardiol 2001;87(5):542-6 (Pubitemid 32178447)
23. Pitt B, O'Neill B, Feldman R, et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001;87(9):1058-63 (Pubitemid 32710319)
24. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362(9386):782-8 (Pubitemid 37093919)
25. Ferrari R. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med 2006;166(6):659-66
26. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340(8829):1173-8
27. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355(9200):253-9
28. Lonn E, Yusuf S, Dzavik V, et al. SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001;103(7):919-25 (Pubitemid 32183795)
29. Bertrand ME, Remme WJ, Fox KM, et al. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function. Int J Cardiol2007;121(1):57-61 (Pubitemid 47285378)
30. Cushman DW, Wang FL, Fung WC, et al. Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am J Hypertens 1989;2(4):294-306 (Pubitemid 19087208)
31. Miyazaki M, Kawamoto T, Okunishi H. Vascular affinity of trandolapril. Am J Hypertens 1995;8(10 Pt 2):63S-67S
32. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318(26):1728-33
33. Davis JO. Adrenocortical and renal hormonal function in experimental cardiac failure. Circulation 1962;25:1002-14
34. Packer M, Medina N, Yushak M, Meller J. Hemodynamic patterns of response during long-term captopril therapy for severe chronic heart failure. Circulation 1983;68(4):803-12 (Pubitemid 13019228)
35. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985;57(1):84-95 (Pubitemid 15238844)
36. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation 1985;72(2):406-12 (Pubitemid 15019891)
37. St John Sutton M, Pfeffer MA, Moye L, et al. Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation 1997;96(10):3294-9 (Pubitemid 27513397)
38. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994;343(8906):1115-22
39. Dagenais GR, Pogue J, Fox K, et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006;368(9535):581-8 (Pubitemid 44209181)
40. Danchin N, Cucherat M, Thuillez C, et al. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials. Arch Intern Med 2006;166(7):787-96
41. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362(9395):1527-35 (Pubitemid 37410190)
42. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27(11):2121-58
43. Brunner HR, Gavras H, Waeber B. Enhancement by diuretics of the antihypertensive action of long-term angiotensin converting enzyme blockade. Clin Exp Hypertens 1980;2(3-4):639-57 (Pubitemid 11230193)
44. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351(13):1285-95 (Pubitemid 39258422)
45. McCullough PA. Why is chronic kidney disease the "spoiler" for cardiovascular outcomes? J Am Coll Cardiol 2003;41(5):725-8 (Pubitemid 36308376)
46. Solomon SD, Rice MM, Aj K, et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation 2006;114(1):26-31 (Pubitemid 44305271)
47. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366(9502):2026-33 (Pubitemid 41773378)
48. Collins AJ, Foley RN, Herzog C, et al. Excerpts from the US Renal Data System 2009 Annual Data Report. Am J Kidney Dis 2010;55(1 Suppl 1):S1-420, A6-7
49. Tuck ML, Bounoua F, Eslami P, et al. Insulin stimulates endogenous angiotensin II production via a mitogen-activated protein kinase pathway in vascular smooth muscle cells. J Hypertens 2004;22(9):1779-85 (Pubitemid 39141971)
50. Hughes DB, Britton ML. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus. Pharmacotherapy 2005;25(11):1602-20 (Pubitemid 41566919)
51. Macisaac RJ, Jerums G. Intensive glucose control and cardiovascular outcomes in type 2 diabetes. Heart Lung Circ 2010. [Epub ahead of print]
52. Davidson MH, Robinson JG. Lipid-lowering effects of statins: a comparative review. Expert Opin Pharmacother 2006;7(13):1701-14
53. Hippisley-Cox J, Coupland C Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis. BMJ 2005;330(7499):1059-63 (Pubitemid 40646559)
54. Sauer WH, Baer JT, Berlin JA, Kimmel SE. Class effect of angiotensin-converting enzyme inhibitors on prevention of myocardial infarction. Am J Cardiol 2004;94(9):1171-3 (Pubitemid 39424223)
55. Manthey J, Osterziel KJ, Rohrig N, et al. Ramipril and captopril in patients with heart failure: effects on hemodynamics and vasoconstrictor systems. Am J Cardiol 1987;59(10):171D-5D (Pubitemid 17071285)
56. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992;117(3):234-42
57. Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet 2000;356(9230):608-9 (Pubitemid 30627581)
58. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic JAMA 2002;288(23):2981-97
59. Ganley CJ, Hung HM, Temple R More on the survival and ventricular enlargement trial. N Engl J Med 1993;329(16):1204-6 (Pubitemid 23295469)
60. Sheifer SE, Manolio TA, Gersh BJ. Unrecognized myocardial infarction. Ann Intern Med 2001;135(9):801-11 (Pubitemid 33051264)
61. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008;29(23):2909-45